Exploring a new treatment for lung cancer with KEAP1 mutations
Investigating the therapeutic potential of a novel glutamine antagonist in KEAP1 mutant lung cancer
['FUNDING_R01'] · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · NIH-11002314
This study is looking at a new treatment for lung cancer that targets a specific part of the cancer cells in patients with certain genetic changes, to see if it can help slow down tumor growth and find out which patients might benefit the most.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11002314 on ClinicalTrials.gov |
What this research studies
This research investigates a novel glutamine antagonist as a potential treatment for lung cancer patients with specific KEAP1 mutations. By using advanced genetic editing techniques, the study aims to understand how these mutations affect cancer cell metabolism and how targeting glutamine can inhibit tumor growth. The research will involve both human and mouse models to assess the effectiveness of this new therapy and identify which patients may benefit the most from it. The goal is to provide a more tailored approach to treating lung cancer based on genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with KRAS-driven lung adenocarcinoma who also have KEAP1 mutations.
Not a fit: Patients without KRAS mutations or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with KEAP1 mutant lung cancer.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways in cancer, suggesting that this approach could yield significant results.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PAPAGIANNAKOPOULOS, THALES — NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- Study coordinator: PAPAGIANNAKOPOULOS, THALES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, cancer metastasis, cancer microenvironment, Cancer Patient